Health Notices




12 APRIL 2012 NEW ZEALAND GAZETTE, No. 41 1227


Health

Health Act 1956

Declaration of the Tamaki Makaurau–Auckland Health District

Pursuant to section 19 of the Health Act 1956, I, Kevin James Woods, Director-General of Health, declare that the health district of Tamaki Makaurau-Auckland shall be established.

The boundaries of the Tamaki Makaurau-Auckland health district shall be deemed to be the boundaries of the land included within the territorial authority district of Auckland.

Consequential to the establishment of the Tamaki Makaurau–Auckland health district, the following health districts are disestablished:

  • North West Auckland
  • Central Auckland
  • South Auckland.

This declaration will come into force on 30 April 2012.

Dated at Wellington this 31st day of March 2012.

KEVIN WOODS, Director-General of Health.

go2198


Medicines Act 1981

Consent to the Distribution of a New Medicine

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicine which was referred to the Minister of Health under the provisions of section 24(5) of the Act and is set out in the Schedule hereto:

Schedule

Product: Glucagen Hypokit
Active Ingredient: Glucagon hydrochloride 1mg
Dosage Form: Powder for injection
New Zealand Sponsor: Novo Nordisk Pharmaceuticals Limited
Manufacturers: Statens Serum Institut, Copenhagen, Denmark
Novo Nordisk A/S, Gentofte, Denmark

Dated this 4th day of April 2012.

DR DON MACKIE, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go2184

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:

Schedule

Product: Allerfix
Active Ingredient: Sodium cromoglicate 2%w/v
Dosage Form: Eye drops, solution
New Zealand Sponsor: Arrow Pharmaceuticals (NZ) Limited
Manufacturer: FDC Limited, District Aurangabad, India

Product: Apo-Pramipexole
Active Ingredient: Pramipexole hydrochloride 0.125mg
Dosage Form: Tablet
New Zealand Sponsor: Apotex NZ Limited
Manufacturer: Apotex Inc, Ontario, Canada

Product: Apo-Pramipexole
Active Ingredient: Pramipexole hydrochloride 0.25mg
Dosage Form: Tablet
New Zealand Sponsor: Apotex NZ Limited
Manufacturer: Apotex Inc, Ontario, Canada

Product: Apo-Pramipexole
Active Ingredient: Pramipexole hydrochloride 0.5mg
Dosage Form: Tablet
New Zealand Sponsor: Apotex NZ Limited
Manufacturer: Apotex Inc, Ontario, Canada



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2012, No 41





✨ LLM interpretation of page content

🏥 Declaration of the Tamaki Makaurau–Auckland Health District

🏥 Health & Social Welfare
31 March 2012
Health District, Tamaki Makaurau-Auckland, Boundaries, Disestablishment
  • Kevin James Woods, Director-General of Health

🏥 Consent to the Distribution of a New Medicine - Glucagen Hypokit

🏥 Health & Social Welfare
4 April 2012
Medicine, Glucagen Hypokit, Glucagon hydrochloride, Novo Nordisk Pharmaceuticals
  • Dr Don Mackie, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health

🏥 Consent to the Distribution of New Medicines - Allerfix and Apo-Pramipexole

🏥 Health & Social Welfare
4 April 2012
Medicines, Allerfix, Apo-Pramipexole, Arrow Pharmaceuticals, Apotex NZ Limited
  • Dr Don Mackie, Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health